{"title":"Racial Disparities, Advanced Ovarian Cancer, and HER2 Expression: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner","authors":"Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC","doi":"10.6004/jadpro.2023.14.6.9","DOIUrl":null,"url":null,"abstract":"Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies. He also describes the phase III DUO-O trial, which evaluated therapies for patients with advanced ovarian cancer without a BRCA1/2 mutation. Finally, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki showed encouraging results in patients with different cancers.","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.6.9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies. He also describes the phase III DUO-O trial, which evaluated therapies for patients with advanced ovarian cancer without a BRCA1/2 mutation. Finally, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki showed encouraging results in patients with different cancers.
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC，辛辛那提癌症顾问，讨论了医疗补助扩大对胃肠道恶性肿瘤患者死亡率种族差异的影响。他还介绍了三期DUO-O试验，该试验评估了无BRCA1/2突变的晚期卵巢癌患者的治疗方法。最后，fam-曲妥珠单抗deruxtecan-nxki的首次肿瘤不可知全球研究在不同癌症患者中显示出令人鼓舞的结果。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
